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In many industrialized countries, since the 1980’s, Group B streptococcus (GBS) became and remains the 
most important pathogen causing neonatal invasive infections, reported attack rates ranging from 1.0 to 4.7 per 
1,000 live births.1-3  As recently demonstrated, up to 75 % of cases can be prevented by an intrapartum 
antibioprophylaxis given to selected women at risk of delivering a neonate who will present shortly after birth a 
severe GBS infection4,5.  As recommended by CDC in 1996, these women can be identified either on a prenatal 
culture-screening based approach or on a risk-based approach.6 Based on data available since 1996, the 
screening approach has been demonstrated more effective than the risk-based approach; therefore, in August 
2002, CDC issued revised guidelines which recommend a universal screening based approach for ALL pregnant 
women.7 Other strategies are still investigational as vaccine or vaginal intrapartum disinfection with 
chlorhexidine.8-12 In Europe, epidemiological data regarding GBS neonatal diseases are rather poor and the 
known or estimated attack rates seem to vary a lot from one country to another.  Some countries, as Spain, have 
already issued guidelines for the prevention of GBS perinatal diseases ; and, from one country to the other, these 
guidelines, if they exist, can be rather different in their recommendations.   
The aim of the Granada GBS workshop was to think about GBS neonatal burden in Europe and to look for 
useful tracks  that European should  follow for the prevention of these GBS perinatal diseases.    
 
Workshop (scientific program attached to this document) 
 
For the success of strategies for prevention for GBS perinatal disease, gynecologist-obstetricians, 
microbiologists, neonatologists and all related heath-care providers should work together as a team and should 
comply with the same recommendations.  To have a useful workshop, the organizing committee minded to invite 
equally either as speaker or as attendee, obstetricians, microbiologists and pediatricians. Nine European 
countries were represented: Austria, Belgium, France, Germany, Italy, Norway, Portugal, Spain and United 
Kingdom, with a great majority of Spaniards. Furthermore, four reference North American speakers were also 
invited: S.Schrag from the CDC in Atlanta, USA, WE.Benitz pediatrician from the Sandford University, USA, 
D.Davies, also pediatrician, from the University of Calgary, Canada, and P. Della-Latta, microbiologist at the 
Columbia Presbyterian Medical Center in New York, USA. 
To introduce the workshop, S.Salcedo and J.Vinzo (Spain) stated the global GBS neonatal burden, 
reviewed the different approaches to prevent perinatal GBS infections and opened some questions for further 
discussion. Than WE.Benitz gave a comparative analysis of GBS prevention strategies and argued benefits, cost-
effectiveness and adverse effects observed or to expect with the different strategies.  After that we got some 
analysis of the European situation with data from UK, France, Italy, Austria, Germany and Spain.  The lowest 
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observed attack rate is 0.5 per 1,000 live births in UK and the highest in France with 4.8 cases of early onset 
disease per 1,000 live births.  From this analysis of the European situation, two main problems have emerged : 
the definition of a case and the method to get or to collect data.  Spanish speakers illustrated the impact of their 
guidelines and their success in reducing strikingly the attack rate of GBS early onset disease, from 2 to 3 per 
1,000 in the mid-1990s to less than 0,5 per 1,000 live births in 2002.   
In the following session, S.Schrag from the CDC presented the first U.S. consensus recommendations 
issued by CDC in 1996 (ACOG 1996 and AAP 1997), their impact, benefits and adverse effects observed or to 
expect, and their re-evaluation in November 2001.  She argued the choice made in the revised guidelines issued 
in 2002, a universal culture-screening based strategy, and stressed things that remain the same and the areas of 
change.  JM Foidart (Belgium), obstetrician, emphasized the importance of systematic attitude, the requirement 
for good documentation and communication (the right information must be at the right place at the right time), the 
importance to be creative finding the means to get gynecologists, microbiologists and pediatricians working 
together as a team and to facilitate compliance to recommendations.  M de la Rosa reviewed all the important 
microbiological characteristics of GBS, methods for detection of GBS, and the improvement and drawbacks to 
expect from culture on Granada agar.  On Granada agar, GBS are very easily detected, they grow as typical 
orange-red colonies.  But the good manufacturing procedures and storage conditions are critical for its quality.  As 
reported by different speakers, rapid PCR detection of GBS could become, rather shortly, a very promising tool in 
prevention strategy. In this session, P. Della-Latta also presented the current microbiological practices for GBS 
screening in the US and suggested some improvements to get a higher sensitivity and a shorter turn-around time 
for GBS prenatal screening cultures.  A.Andreu (Spain) confirmed the reduction in the attack rate of GBS neonatal 
diseases observed in Spain consecutively to implementation of the Spanish guidelines.  She also stressed 
advantages of direct plating and subculturing Lim broth onto Granada medium agar for the prenatal screening.  
The third session dealt with neonatal management and special problems. D.Davies, from Canada, 
reported the successful Canadian experience in reducing incidence of perinatal GBS diseases and debated 
special problems as incomplete prophylaxis, cesarean delivery and allergies to penicillin.  Than WE.Benitz 
reviewed controversies and uncertainties regarding the management of babies at risk for GBS disease as 
reflected through CDC’s guidelines.  He proposed to stratify babies in intermediate and high risk babies and gave 
suggestions for their management, evaluation and treatment.  In summary, he suggested no intervention for well 
infants without maternal risk factors, diagnostic evaluation and empiric treatment of infants born to women with 
PPROM or chorioamnionitis, and those with signs of illness, and postpartum prophylaxis or limited diagnostic 
evaluation for intermediate risk infants (identified by risk criteria).  In this session, another very interesting 
approach for prevention was also reported and could probably be integrated in the future in a new strategy for 
prevention.  B.Stray-Pettersen from Norway, reported a very interesting and impressive reduction of GBS early 
onset disease obtained with a universal vaginal intrapartum douching with 140 ml of a solution of chlorexidine 
(every 6 hours until delivery) combined with intrapartum antimicrobial prophylaxis for selected high risk . 
All these different presentations were opened for discussion and were followed by an interactive session. 
For the last session, an interactive session, each participant had received an individual keypad to vote 
electronically “ in real time” on each key point of a strategy they would like to recommend in Europe for the 
prevention of perinatal GBS diseases.  To have an idea of non Spanish European votes, results were gathered in 
two categories Spaniards (SP) and non Spanish European (EU). To reach a consensus, we fixed an 80 % cut-off 
of agreement between participants. 
Interactive session : summary of the results  
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Who should issued guidelines to get the highest compliance level ?  Before starting with 
guidelines to recommend in Europe, the attendance was asked to give its opinion regarding the type of guidelines 
which could get the highest level of compliance.  There was no difference between SP and EU participants’ 
opinion: 57% believed that European guidelines would be the best, 15% thought that national guidelines would be 
better and the others thought that it does not matter if guidelines were European or national. The same question 
was asked regarding the organization that would issue these guidelines.  They could choose between Department 
of Public Health, one of the related professional and scientific European societies (ESCMID, Obstetrics and 
gynecology or Pediatrics), and all these three societies together, after a consensus.   For EU participants it was 
clear, 93% thought future guidelines should be launched after a consensus by all three European societies, only 
7% would prefer a Department of Public Health.  Among SP, 74%  agreed with the choice of the three societies, 
12 % with the Public Health department and 14% believed in compliance even if guidelines were launched by only 
one of the three Societies.      
“Ideal” strategy to recommend in Europe.  Among SP, who already have guidelines 
recommending selective intrapartum antimicrobial prophylaxis based on a universal screening strategy, 69% 
would recommend the same, 4% would prefer a risk-based approach, 12.5% would like to have both alternatives 
and 12.5% would like a new approach combining selective antimicrobial prophylaxis with universal or selective 
vaginal desinfection.  Only 47% of EU were in favor of a universal prenatal screening based strategy, no one 
would recommend a unique risk-based approach but 27% would prefer to recommend both approaches as in the 
previous CDC recommendations.  As some SP did, 20% of EU would like to propose a new approach combining 
selective antimicrobial prophylaxis with universal or selective vaginal desinfection.  It’s interesting that a few SP 
(2%) or EU (7%) did not want to recommend anything for prevention of GBS diseases.   
If a selective intrapartum antimicrobial prophylaxis based on a universal screening strategy should be 
recommended in Europe, 54% of the EU participants thought, that in their country, it could be achievable within a 
few months, 38% thought it would not be possible for logistic problems and 8% for financial reasons (national 
health budget, level of reimbursement for cultures, etc.).  For SP, of course it was quite different and 88% thought 
it would be shortly achievable, however 5% opposed financial problems and 2% logistic problems. 
If a clinically proven effective rapid GBS screening test became available, half of the participants either SP 
or EU would be in favor of their integration into the screening based strategy for an rapid screening at admission 
of women fordelivery.  For nearly 40% of EU and 20% of SP, the major obstacle to this issue was that too many 
hospitals or clinics do not have adequate laboratory facilities 24 hours a day, 7 days a week.  Only one EU and 
21% of SP did not believe the benefit could balance their drawbacks. 
Related to the antimicrobial agent to recommend as first choice, all EU except one would recommend 
“Penicillin G”  at 5 MIU IV initial dose + 2.5 MIU IV every 4 hours until delivery as the most appropriate regimen.  
Among SP, only 73% agreed with this choice and 24% would recommend another agent.  Unfortunately, none of 
them wanted to comment their opinion.  For the alternative to recommend in penicillin-allergic patients, the 
opinions were more scattered.  Only 35% of EU and 29% of SP would recommend Cefazolin for penicillin-allergic 
patients not at high risk for anaphylaxis, which is the drug currently recommended by CDC guidelines.  In fact 
data relative to clindamycin and erythromycin resistance for GBS in Europe are still very poor, even if some data 
as from Belgium, showed a trend in emergence of resistance (10-15% in 2002). 
Regarding the clinical specimens to collect for the GBS prenatal screening, 80% of EU and 93% of SP 
would recommend both vaginal and rectal swabs.  No EU would recommend a vaginal swab alone but 20% would 
propose other specimens.  For the laboratory procedure for prenatal GBS cultures, many of participants were 
convinced to use Granada medium agar, either by their own practice for SP or by the different data presented 
along the meeting: 64% of EU and 87% of SP would recommend either direct plating or subculturing from Lim 
broth onto Granada medium. 
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One major problem for pediatricians, related to selective antimicrobial prophylaxis prevention strategy, is 
the management of asymptomatic newborns exposed to intrapartum prophylaxis.  Convinced by Dr Benitz’s data 
and based on their own experience, 67% of EU and 54% of SP would consider a full diagnostic evaluation and 
giving an empiric antimicrobial therapy at least 48 hours to asymptomatic neonates born to a mother with at least 
two of the following risk factors: GBS vaginal colonization, < 35 weeks gestation, intrapartum T° >= 38° C, 
prolonged rupture of membranes > 18 hours; furthermore, 28% of EU and 36% of SP would also recommend the 
same attitude when the mother received antibiotics for a suspected chorio-amnionitis.     
As the GBS neonatal epidemiology has been rather dynamic in the last three decades and with guidelines 
to reduce the GBS neonatal burden implemented in different countries, surveillances to monitor incidence of GBS 
and non-GBS early onset diseases, to monitor risk factors associated with early onset diseases and the potential 
adverse effects of chemoprophylaxis, are desirable.  Most of SP (88%) and of EU (75%) were ready to participate 




Summary and concluding remarks (P. Melin, Belgium  and C. McCartney, UK) 
 
• Associated to high morbidity and mortality, infection due to S.agalactiae either in newborn infants or their 
prevention is also a major public health problem in Europe. Some differences exist between different 
European countries and few of them have already issued guidelines for the prevention of neonatal GBS 
diseases.   
• Epidemiological surveillances and a standardized definition of cases would be highly desirable.   
• From the different speakers, clearly the success of recommendations to reduce the GBS burden by preventing 
early onset neonatal GBS diseases is linked to cooperation between the different partners dealing with health 
care to pregnant women and with deliveries.  Obstetricians, microbiologists, pediatricians and all related 
health-care providers have to work as a TEAM.  They have to organize a good communication of results and 
observations to the right person, at the right place as soon as available.    
• A consensus was reached to wish common guidelines issued by obstetrics, microbiology and infectious 
diseases and pediatrics European societies.   
• Even if a prenatal screening based approach to identify mothers with an indication for antimicrobial 
prophylaxis was evidently more effective than a risk-based approach, a consensus was not reached within the 
attendance, but only a majority in favor with the screening approach.  For the prenatal screening, a consensus 
was reached to recommend both vaginal and rectal swabs for the clinical specimens to collect.   
• Regarding laboratory procedure for prenatal screening cultures, the Granada medium agar as a selective 
differential medium for GBS would be recommended by a majority of the participants either as primary culture 
or for subculturing Lim Broth. 
• Interestingly, more than 50% would integrate rapid intrapartum testing for GBS screening when a relevant test 
would become available.   
• Another important learning during this meeting was the demonstration of efficacy of the Norwegian strategy to 
reduce the attack rate of GBS neonatal disease.   This strategy, based on a universal intrapartum vaginal 
desinfection with chlorexidine has attracted numerous participants.    
• For the antimicrobial agent to recommend for the intrapartum antimicrobial prophylaxis, a consensus was 
reached for Penicillin G, but opinions were less clear regarding the alternative agent to recommend for 
penicillin-allergic women.     
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• For the management of asymptomatic neonates exposed to prophylaxis, a majority of participants would like 
to consider a full diagnostic evaluation and giving an empiric antimicrobial therapy at least 48 hours to 
selected high risk neonates. 
For the future :   
• European are currently too far from each other to propose a consensus for the prevention of neonatal GBS 
diseases.  First, surveillances are needed.  ESCMID could play a role in encouraging and funding a European 
surveillance of GBS and non-GBS early onset neonatal diseases.  A great majority of the participants at the 
Granada GBS Workshop have already agreed to involve their institution in such surveillance.  
• All the European participants and invited North American speakers were really pleased by such an interesting 
and fruitful meeting.  Unanimously, everybody expressed the wish to have a second enlarged European GBS 
workshop within the next two years.   
• To organize either this second workshop or a European surveillance, C.McCartney (UK), G.Orefici (Italy) and 
P.Melin (Belgium) are very interested to involve themselves.   
 
If ESCMID agrees, even if we are not ready to prepare a consensus paper, proceedings of the workshop could be 
published in a supplement of the “Clinical Microbiology and Infection”.  Most of the speakers have already 
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Official language:English.    Traducción simultanea a español  
 
SESSION I Chairperson: Dr JC Santiago.Obstetrics & Gynaecology.Hosp.Virgen Nieves.Granada.Spain 
Introductory remarks. Dr L Cabero, President Spanish Soc. Obstetrics & Gynaecology. Univ.Hosp. Vall 
d´Hebron. Barcelona 
GBS neonatal disease, overview of the burden and the challenge of diagnosing neonatal bacterial 
sepsis. Dr S Salcedo and Dr J Vinzo. Neonatology. Univ.Hosp.Vall d´Hebron 
Analysing  prevention strategies. Dr WE. Benitz. Depart. Pediatrics, Stanford Univ. School Medicine, CA. 
USA 
The European situation. The UK GBS Surveillance.  Dr P Heath. St George's Hosp. Medical School. 
London.UK 
France.  Dr L Mereghetti. Microbiol. Univ.Tours, France 
Italy. Dr G Orefici. Istit.Superiore Sanità.Roma. Italy 
Austria and Germany.  Dr K Schuchter. Ludwig Boltzman Inst. Clinical Obstetrics & Gynecology. 
Donauspital. Vienna, Austria 
The UK practice. The obstetrician’s opinion. Dr R Hughes, Royal Infirmary. Edinburgh.UK 
Assessing the severity of the problem: “The Castrillo Group”.  Dr J Lopez Sastre. Neonatology. Oviedo 
and Dr M Sanchez Luna. Neonatology Univ.Hosp.Gregorio Marañón. Madrid  
Questions 
 
   
SESSION II Chairpersons: Dr J Quero. and Dr J Perez Rodiguez. Neonatology. Univ.Hosp.La Paz. Madrid  
GBS in the antenatal clinic and in the delivery room: a matter of systematic attitude. Dr JM Foidart. 
President Belgian Royal Soc.Gynecology & Obstetrics. Univ.Hosp.Liège.Belgium 
The microbiologist´s perspective. Dr M de la Rosa. Microbiology. Univ. Hosp. Virgen Nieves. Granada 
The CDC guidelines and their impact.  Dr S Schrag, CDC. Atlanta. USA 
GBS screening in US, current microbiological practice. Dr P Della-Latta. Microbiology. Columbia 
Presbyterian Medical Center. NewYork. USA 
The Spanish Guidelines and experience and the situation in Portugal. Dr A Andreu, Microbiol. Univ. 
Hosp. Vall d´Hebron and Dr F Exposto.Inst. Higiene e Medicina Tropical. Lisbon. Portugal 
Debate & Questions 
 
 
SESSION III  Chairpersons: Dr M de la Rosa and Dr E J Perea. Medical Microbiology.Univ. Sevilla  
The Canadian Experience. Dr D Davies, Dep.Microbiology & Infectious Disease, Pediatrics & Community 
Health, Alberta Children's Hosp. Calgary Univ. Canada 
The threat of resistant E. coli, myth or reality.  Dr F Omeñaca and Dr A Alarcon. Neonatology. 
Univ.Hosp.La Paz 
GBS neonatal disease prevention. Screening-based vs risk-based approaches. Dr G Gopal  Rao. 
Microbiology. Lewisham Hosp. London. UK 
Prevention of GBS transmission in labour: the topical approach. Dr GC di Renzo. Perinatal & 
Reproductive Medicine. Univ. Perugia and Dr F Facchinetti. Univ. Modena. Italy 
How to manage a neonate born to a mother with risk factors for GBS disease. Dr WE Benitz 
Special problems: Incomplete prophylaxis, caesarean delivery, allergies. Dr D Davies 
Debate & Questions 
 
 
SESSION IV  Chairperson: Dr P Melin, Medical Microbiology. Univ.Hosp. Liege, Belgium 
Round table and Interactive session  
Summing up. Dr P Melin 
Concluding remarks: Is a European opinion worthwhile and possible? Dr L Cabero   
 
